Adaptimmune Partners With Genentech to Develop iPSC-derived Allogeneic TCR-Ts
On Tuesday, September 7, Adaptimmune announced (press release) a strategic collaboration and license agreement with Genentech (Roche) to develop and commercialize allogeneic T cell therapies for multiple oncology indications. Of note, Adaptimmune will receive $150M upfront and further milestone payments potentially exceeding $3B in aggregate value. Below, Celltelligence provides insights on how Genentech (Roche) could leverage their extensive capabilities to quickly advance allogeneic TCR-Ts into the clinic, while discussing Adaptimmune’s strategy to become a leader in the allogeneic TCR-T space.